Search

Your search keyword '"Carlo Buonerba"' showing total 5 results
Start Over Author "Carlo Buonerba" Journal future oncology (london, england)
5 results on '"Carlo Buonerba"'

1. The emerging role of obesity, diet and lipid metabolism in prostate cancer

Author

Danilo Bottero, Matteo Ferro, Giuseppe Lucarelli, Riccardo Autorino, Sisto Perdonà, Daniela Terracciano, Iulia Andras, Giuseppe Di Lorenzo, Vincenzo Mirone, Carlo Buonerba, A. Serino, Barbara Alicja Jereczek-Fossa, Sabino De Placido, Rocco Damiano, Michele Battaglia, Francesco Cantiello, Ottavio De Cobelli, Ferro, Matteo, Terracciano, Daniela, Buonerba, Carlo, Lucarelli, Giuseppe, Bottero, Danilo, PerdonÃ&nbsp, Sisto, Autorino, Riccardo, Serino, Alessandro, Cantiello, Francesco, Damiano, Rocco, Andras, Iulia, De Placido, Sabino, Di Lorenzo, Giuseppe, Battaglia, Michele, Jereczek-Fossa, Barbara A, Mirone, Vincenzo, De Cobelli, Ottavio, Perdonà, Sisto, DE PLACIDO, Sabino, DI LORENZO, Giuseppe, and Jereczek Fossa, Barbara A

Subjects
0301 basic medicine, Oncology, Male, medicine.medical_specialty, Cancer Research, medicine.drug_class, Review, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Internal medicine, medicine, Adipocytes, Humans, urologic/prostate, Obesity, Prostate cancer risk, Adipocyte, business.industry, Prostate cancer mortality, Cancer, Prostatic Neoplasms, Lipid metabolism, General Medicine, Androgen, medicine.disease, Lipid Metabolism, Diet, 030104 developmental biology, Cell Transformation, Neoplastic, Dietary fat intake, 030220 oncology & carcinogenesis, Prostatic Neoplasm, business, Human
Abstract

Obesity is associated with an increased risk of a number of serious medical conditions, including cancer. As far as prostate cancer is concerned, obesity is associated with an increased risk of high-grade tumors, which is possibly related to lower androgen levels. Diet may also affect prostate cancer risk since countries with a higher dietary fat intake also present higher prostate cancer mortality rates. Interestingly, prostate cancer is associated with a number of metabolic alterations that may provide valuable diagnostic and therapeutic targets. This review explores the available clinical as well as biological evidence supporting the relationship between obesity, diet, alteration in metabolic pathways and prostate cancer.

Published
2016

2. The role of immunotherapy in oncology

Author

Vittorio Riccio, Carlo Buonerba, Simone Carrano, and Giuseppe Di Lorenzo

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Cancer, Ipilimumab, General Medicine, Immunotherapy, medicine.disease, Sipuleucel-T, Internal medicine, Neoplasms, medicine, Humans, Nivolumab, business, medicine.drug
Published
2015

3. Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer

Author

Guru Sonpavde, Sabino De Placido, Vincenzo Altieri, Matteo Ferro, Paolo Grieco, Massimiliano Berretta, Sisto Perdonà, I. Coman, Claudia Manini, Giuseppe Lucarelli, Gaetano Facchini, Vincenzo Mirone, Carlo Buonerba, Pierluigi Bove, Ettore Novellino, Michele Caraglia, Renato Franco, Ottavio De Cobelli, Giuseppe Di Lorenzo, Daniela Terracciano, Danilo Bottero, De Cobelli O1, 2, Buonerba, C, Terracciano, D, Bottero, D, Lucarelli, G, Bove, P, Altieri, V, Coman, I, Perdonà, S, Facchini, G, Berretta, M, Di Lorenzo, G, Grieco, P, Novellino, E, Franco, R, Caraglia, M, Manini, C, Mirone, V, De Placido, S, Sonpavde, G, Ferro, M, De Cobelli, Ottavio, Buonerba, Carlo, Terracciano, Daniela, Bottero, Danilo, Lucarelli, Giuseppe, Bove, Pierluigi, Altieri, Vincenzo, Coman, Ioman, Perdonà, Sisto, Facchini, Gaetano, Berretta, Massimiliano, Di Lorenzo, Giuseppe, Grieco, Paolo, Novellino, Ettore, Franco, Renato, Caraglia, Michele, Manini, Claudia, Mirone, Vincenzo, DE PLACIDO, Sabino, Sonpavde, Guru, and Ferro, Matteo

Subjects
Oncology, Male, medicine.medical_specialty, Cancer Research, Multivariate analysis, medicine.medical_treatment, Biopsy, Urotensin-II receptor, Gleason score, prostate cancer, urotensin II receptor, Settore MED/24 - Urologia, Receptors, G-Protein-Coupled, Prostate cancer, G-Protein-Coupled, Internal medicine, Receptors, medicine, Humans, Aged, Neoplasm Staging, Retrospective Studies, Prostatectomy, medicine.diagnostic_test, business.industry, Prostatic Neoplasms, Retrospective cohort study, General Medicine, Odds ratio, Middle Aged, medicine.disease, Disease Progression, Lymphatic Metastasis, Neoplasm Grading, Preoperative Period, Immunohistochemistry, business, Research Article
Abstract

Aim: A higher Gleason score was associated with a lower tumor urotensin II receptor (UTII-R) expression in prostate cancer patients. Methods: A retrospective review of formalin-fixed paraffin-embedded tumor tissue derived from those who had prostatectomy and matching biopsy specimens was conducted at six Institutions. UTII-R expression was evaluated on biopsy by immunohistochemistry. Results: A total of 58 subjects undergoing radical prostatectomy were included. At multivariate analysis, low UTII-R expression was a significant predictor of Gleason upgrading, with an odds ratio of 10.3 (95% CI: 1.55–68.4), and of pathology upstaging, with an odds ratio of 11.1 (95% CI: 1.23–100.48). Conclusions: UTII-R expression on biopsy was associated with Gleason upgrading and pathology upstaging in prostate cancer patients.

Published
2015

4. Is in vitro-acquired resistance to enzalutamide a useful model?

Author

Carlo Buonerba and Giuseppe Di Lorenzo

Subjects
Oncology, Male, Cancer Research, medicine.medical_specialty, chemistry.chemical_compound, Acquired resistance, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Nitriles, Phenylthiohydantoin, medicine, Enzalutamide, Humans, business.industry, General Medicine, In vitro, Abiraterone, Prostatic Neoplasms, Castration-Resistant, chemistry, Cabazitaxel, Drug Resistance, Neoplasm, Benzamides, Taxoids, business, medicine.drug
Published
2014

5. Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients

Author

Tania Policastro, Piera Federico, Giuseppina Della Vittoria Scarpati, Francesco Perri, Ciro Imbimbo, Ottavio De Cobelli, Sabino De Placido, Carlo Buonerba, Michele Aieta, Davide Bosso, Nicola Longo, Michela Izzo, Matteo Ferro, Giuseppe Di Lorenzo, Livio Puglia, Buonerba, C, Federico, P, Bosso, D, Puglia, L, Policastro, T, Izzo, M, Perri, F, Vittoria Scarpati, Gd, Ferro, M, Cobelli, Od, DE PLACIDO, Sabino, Aieta, M, Imbimbo, Ciro, Longo, Nicola, and Di Lorenzo, G.

Subjects
Oncology, Male, Cancer Research, medicine.medical_specialty, Carboplatin, chemistry.chemical_compound, Prostate cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Enzalutamide, Humans, Neoplasm Metastasis, Etoposide, Aged, business.industry, General Medicine, Prostate-Specific Antigen, medicine.disease, Combined Modality Therapy, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, chemistry, Docetaxel, Cabazitaxel, Neoplasm Grading, business, Progressive disease, medicine.drug
Abstract

ABSTRACT: Aims: Carboplatin plus etoposide has modest efficacy in docetaxel-pretreated castration-resistant prostate cancer patients. We hypothesized that carboplatin–etoposide could still exert some therapeutic activity after docetaxel, cabazitaxel and either abiraterone or enzalutamide. Patients & methods: We enrolled 15 patients in the first step of a Phase II trial. The target sample size is 46 patients. The primary end point of the study was progression-free survival after 12 weeks. Results: The median progression-free survival was 11 weeks (range: 8–18), while median overall survival was 18 weeks (range: 12–26). Of seven patients with measurable disease, two had a partial response, two showed stable disease and the remaining three had progressive disease as the best radiological response. Five patients were considered progression-free after 12 weeks, prompting continuation of the trial. Conclusion: Our preliminary findings support the hypothesis that carboplatin plus etoposide may yield some clinical benefit in a population of patients who failed all currently approved therapeutic options for prostate cancer.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results